Criteria for the treatment of chronic hepatitis B and D;Indikationsstellung zur therapie der chronischen hepatitis B und D

Zeitschrift fur Gastroenterologie

Volumn 42, Issue 8, 2004, Pages 682-686

  Niederau, Claus ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B(E) ANTIGEN;

CHRONIC HEPATITIS; DELTA AGENT HEPATITIS; HEPATITIS B; HUMAN; LIVER CELL CARCINOMA; LIVER FUNCTION; REVIEW; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; VIRUS REPLICATION;

GERMANY; HEPATITIS B, CHRONIC; HEPATITIS D, CHRONIC; HUMANS; PATIENT CARE MANAGEMENT; PRACTICE GUIDELINES; PROGNOSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX;

EID: 4444290144     PISSN: 00442771     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-813437     Document Type: Review

References (63)

1. McMahon BJ, Alward WLM, Hall DB et al. Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. J Infect Dis 1985; 151: 599-603 (III)
2. Tassopoulos NC, Papaevangelou GJ, Sjogren MH et al. Natural history of acute hepatitis B surface antigen-positive hepatitis in Greek adults. Gastroenterology 1987; 92: 1844-1850 (III)
3. Hsu YS, Chien RN, Yeh CT et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology 2002; 35: 1522-1527 (III)
4. Niederau C, Heintges T, Lange S et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996; 334: 1422-1427 (Ib)
5. Realdi G, Alberti A, Rugge M et al. Seroconversion from hepatitis B e antigen to anti-HBe in chronic hepatitis B virus infection. Gastroenterology 1980; 79: 195-199 (III)
6. Hoofnagle JH, Dusheiko GM, Seef LB et al. Seroconversion from hepatitis B e antigen to antibody in chronic type B hepatitis. Ann Intern Med 1981; 94: 744-748 (III)
7. Sánchez-Tapias JM, Vilar JH, Costa J et al. Natural history of chronic persistent hepatitis B. Relationship between hepatits B virus replication and the course of the disease. J Hepatol 1984; 1: 15-27 (III)
8. Fattovich G, Rugge M, Brollo L et al. Clinical, virologic and histologic outcome following seroconversion from HBeAg to anti-HBe in chronic hepatitis type B. Hepatology 1986; 6: 167-172 (III)
9. Bortolotti F, Jara P, Crivellaro C et al. Outcome of chronic hepatitis B in Caucasian children during a 20-year observation period. J Hepatol 1998; 29: 184-190 (III)
10. Evans AA, Fine M, London WT. Spontaneous seroconversion in hepatitis B e antigen-positive chronic hepatitis B: implications for interferon therapy. J Infect Dis 1997; 176: 845-850 (III)
11. Chang MH, Sung JL, Lee CY et al. Factors affecting clearance of hepatits B e antigen in hepatitis B surface antigen carrier children. J Pediatr 1989; 115: 385-390 (III)
12. Bortolotti F, Cadrobbi P, Crivellaro C et al. Long-term outcome of chronic type B hepatitis in patients who acquire hepatitis B virus infection in childhood. Gastroenterology 1990; 99: 805-810 (III)
13. Wong DKH, Cheung AM, O'Rourke K et al. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 1993; 119: 312-323 (Ia)
14. Vajro P, Migliaro F, Fontanella A et al. Interferon: a meta-analysis of published studies in pediatric chronic hepatitis B. Acta Gastroenterol Belg 1998; 61: 219-223 (Ia)
15. Yuen MF, Hui CK, Cheng CC et al. Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: the effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications. Hepatology 2001; 34: 139-145 (III)
16. Perrillo RP, Schiff ER, Davis GL et al. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group. N Engl J Med 1990; 323: 295-301 (Ib)
17. Lok AS, Lai CL, Wu PC et al. Long-term follow-up in a randomised controlled trial of recombinant alpha 2-interferon in Chinese patients with chronic hepatitis B infection. Lancet 1988; 2: 298-302 (Ib)
18. Williams SJ, Craig Pl, Cooksley WG et al. Randomised controlled trial of recombinant human interferon-alpha A for chronic active hepatitis B. Aust N Z J Med 1990; 20: 9-19 (Ib)
19. Lok AS, Wu PC, Lai CL et al. A controlled trial of interferon with or without prednisone priming for chronic hepatitis B. Gastroenterology 1992; 102 (6): 2091-2097 (Ib)
20. Di Bisceglie AM, Fong TL, Fried MW et al. A randomized, controlled trial of recombinant alpha-interferon therapy for chronic hepatitis B. Am J Gastroenterol 1993; 88: 1887-1892 (Ib)
21. Wong DK, Yim C, Naylor CD et al. Interferon alfa treatment of chronic hepatitis B: randomized trial in a predominantly homosexual male population. Gastroenterology 1995; 108: 165-171 (Ib)
22. Korenman J, Baker B, Waggoner J et al. Long-term remission of chronic hepatitis B after alpha-interferon therapy. Ann Intern Med 1991; 114: 629-634 (III)
23. Moreno-Otero R, Garcia-Monzón C, Garcia-Sánchez A et al. Development of cirrhosis after chronic type B hepatitis: a clinicopathologic and follow-up study of 46 HBeAg-positive asymptomatic patients. Am J Gastroenterol 1991; 86: 560-564 (III)
24. Zarski JP, Marcellin P, Cohard M et al. Comparison of anti-HBe-positive and HBe-antigen-positive chronic hepatitis B in France. J Hepatol 1994; 20: 636-640 (III)
25. Di Marco V, Lo lacono O, Cammá C et al. The long-term course of chronic hepatitis B. Hepatology 1999; 30: 257-264 (III)
26. Liaw YF, Tai Dl, Chu CM et al. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology 1988; 8: 493-496 (III)
27. Lin SM, Sheen IS, Chien RN et al. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 1999; 29: 971-975 (III)
28. Fattovich G, Brollo L, Giustina G et al. Natural history and prognostic factors of chronic hepatitis type B. Gut 1991; 32: 294-298 (III)
29. Ikeda K, Saitoh S, Suzuki Y et al. Disease progression and hepatocellular carcinogenensis in patients with chronic viral hepatitis: a prospective observation in 2215 patients. J Hepatol 1998; 28: 930-938 (III)
30. Mazzella G, Saracco G, Festi D et al. Long-term results with interferon therapy in chronic type B hepatitis: a prospective randomized trial. Am J Gastroenterol 1999; 94: 2246-2250 (Ib)
31. Perillo RP. Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology 2001; 120: 1009-1022 (III)
32. Liaw YF, Tai Dl, Chu CM et al. Early detection of hepatocellular carcinoma in patients with chronic type B hepatitis. A prospective study. Gastroenterology 1985; 90: 263-267 (III)
33. Realdi G, Fattovich G, Hadziyannis S et al. Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study. J Hepatol 1994; 21: 656-666 (III)
34. Fattovich G, Giustina G, Christensen E et al. Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. Gut 2000; 46: 420-426
35. Dejongh FE, Janssen HLA, De Man RA et al. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology 1992; 103: 1630-1635 (III)
36. Fattovich G, Giustina G, Realdi G et al. Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa. Hepatology 1997; 26: 1338-1342 (III)
37. Fattovich G, Giustina G, Schalm SW et al. Occurrence of hepatocellular carcinoma and decompensation in Western European patients with cirrhosis type B. Hepatology 1995; 21: 77-82 (III)
38. Chan HLY, Leung NWY, Hussain M et al. Hepatitis B e antigen-negative chronic hepatitis B in Hong Kong. Hepatology 2000; 31: 763-768 (III)
39. Hadziyannis SJ, Vassilopoulos D. Hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2001; 34: 617-624
40. Funk ML, Rosenberg DM, Lok ASF. World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants. J Viral Hepat 2002; 9: 52-61 (III)
41. Rizzetto M, Volpes R, Smedile A. Response of pre-core mutant chronic hepatitis B infection to Lamivudin. J Med Virol 2000; 61: 398-402 (III)
42. Brunette MR, Oliveri F, Coco B et al. Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. J Hepatol 2002; 36: 263-270 (III)
43. Papatheodoridis GV, Manesis E, Hadziyannis SJ. The long-term outcome of interferon-a treated and untreated patients with HBeAg-negative chronic hepatitis B. J Hepatol 2001; 34: 306-313 (III)
44. Alward WLM, McMahon BJ, Hall DB et al. The long-term serological course of asymptomatic hepatitis B virus carriers and the development of primary hepatocellular carcinoma. J Infect Dis 1985; 151: 604-609 (III)
45. Fattovich G, Giustina G, Sanchez-Tapias J et al. Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis. Am J Gastroenterol 1998; 93: 896-900 (III)
46. Liaw YF, Sheen IS, Chen TJ et al. Incidence.determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection: a prospective study. Hepatology 1991; 13: 627-631 (III)
47. Orito E, Mizokami M, Sakugawa H et al. A case-control study for clinical and molecular biological differences between hepatitis B viruses of genotype B and C. Japan HBV Genotype Research Group. Hepatology 2001; 33: 218-223 (III)
48. Yu MW, Hsu FC, Sheen IS et al. Prospective study of hepatocellular carcinoma and liver cirrhosis in asymptomatic chronic hepatitis B virus carriers. Am J Epidemiol 1997; 145: 1039-1047 (III)
49. McMahon BJ, Bulkow L, Harpster A et al. Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: a 16-year population based study. Hepatology 2000; 32: 842-846 (III)
50. McMahon BJ, Holck P, Bulkow L et al. Serologie and clinical outcomes of 1536 Alaska natives chronically infected with hepatitis B virus. Ann Intern Med 2001; 135: 759-768 (III)
51. Lok ASF, Lai CL, Wu PC et al. Spontaneous hepatits B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection. Gastroenterology 1987; 92: 1839-1843 (III)
52. Davis GL, Hoofnagle JH, Waggoner JG. Spontaneous reactivation of chronic hepatitis B virus infection. Gastroenterology 1984; 86: 230-235 (III)
53. Fattovich G, Brollo L, Alberti A et al. Spontaneous reactivation of hepatitis B virus infection in patients with chronic type B hepatitis. Liver 1990; 10: 141-146 (III)
54. Yeo W, Chan PK, Zhong S et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 2000; 62: 299-307 (III)
55. Shibolet O, Ilan Y, Gillis S et al. Lamivudin therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers. Blood 2002; 100: 391-396 (IIa)
56. Rossi G, Pelizzari A, Motta M et al. Primary prophylaxis with Lamivudin of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy. Br J Haematol 2001; 115: 58-62 (III)
57. Markovic S, Drozina G, Vovk M et al. Reactivation of hepatitis B but not hepatitis C in patients with malignant lymphoma and immunosuppressive therapy. A prospective study in 305 patients. Hepatogastroenterology 1999; 46: 2925-2930 (III)
58. Kao JH, Chen PJ, Lai MY et al. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology 2000; 118: 554-559 (III)
59. Chan HL, Tsang SW, Liew CT et al. Viral genotype and hepatitis B virus DNA levels are correlated with histological liver damage HBeAg-negative chronic hepatitis B virus infection. Am J Gastroenterol 2002; 97: 406-412 (III)
60. Liaw YF, Lin DY, Chen TJ et al. Natural course after the development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Liver 1989; 9: 235-241 (III)
61. Beasley RP. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer 1988; 61: 1942-1956
62. McMahon BJ, Alberts SR, Wainwright RB et al. Hepatitis B-related sequelae. Prospective study in 1400 hepatitis B surface antigen-positive Alaska Native carriers. Arch Intern Med 1990; 150: 1051-1054 (III)
63. Benvegnù L, Fattovich G, Noventa F et al. Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma in cirrhosis. Cancer 1994; 74: 2442-2448 (III)